D. Ross Camidge, MD, PhD, is a professor of medicine-medical oncology, and director of the Thoracic Oncology Clinical Program and Clinical Research Program at the University of Colorado Cancer Center – Anschutz Medical Campus.

Ross Camidge, MD, PhD discusses is a pivotal phase II/III clinical trial (ARROS-1) evaluating the efficacy and safety of zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received tyrosine kinase inhibitor (TKI) therapy.

Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pretreated Patients with Advanced/Metastatic ROS1+ NSCLC

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Ross Camidge, MD, PhD, discusses a pivotal phase 2/3 clinical trial (ARROS-1) evaluating the efficacy and safety of zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who have previously received tyrosine kinase inhibitor (TKI) therapy.

Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pretreated Patients With Advanced/Metastatic ROS1+ NSCLC